Subject(s)
Leukemia L1210/drug therapy , Leukemia, Experimental/drug therapy , Streptozocin/therapeutic use , Animals , Cell Division/drug effects , Cells, Cultured , DNA, Neoplasm/biosynthesis , Dose-Response Relationship, Drug , Female , Fibroblasts , Mice , Neoplasm Proteins/biosynthesis , RNA, Neoplasm/biosynthesis , Streptozocin/administration & dosage , Streptozocin/pharmacology , Time FactorsSubject(s)
Antineoplastic Agents/therapeutic use , Naphthalenes/therapeutic use , Quinazolines/therapeutic use , Administration, Oral , Animals , Benzene Derivatives/therapeutic use , Carbon Isotopes , Cells, Cultured , DNA, Neoplasm/biosynthesis , Female , Injections, Intraperitoneal , Injections, Subcutaneous , Ketones/therapeutic use , Leukemia L1210/drug therapy , Leukemia L1210/metabolism , Leukemia, Experimental/drug therapy , Mice , Mice, Inbred Strains , Neoplasm Proteins/biosynthesis , Neoplasm Transplantation , Organ Size , Quinolines/therapeutic use , RNA, Neoplasm/biosynthesis , Time FactorsSubject(s)
Antineoplastic Agents/pharmacology , Cycloparaffins/pharmacology , Cytarabine/pharmacology , Leukemia L1210/drug therapy , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/blood , Antineoplastic Agents/metabolism , Carboxylic Acids/pharmacology , Carcinoma, Squamous Cell , Cell Line/drug effects , Cells, Cultured/drug effects , Cytarabine/administration & dosage , Cytarabine/blood , Cytarabine/metabolism , Cytarabine/urine , DNA, Neoplasm/biosynthesis , Deamination , Delayed-Action Preparations , Depression, Chemical , Half-Life , Haplorhini , Humans , Hydrolysis , In Vitro Techniques , Leukemia L1210/metabolism , Mice , Neoplasm Proteins/biosynthesis , Physostigmine , Plasma , RNA, Neoplasm/biosynthesis , Tritium , UridineSubject(s)
Leukemia L1210/pathology , Nucleosides/toxicity , Animals , Cell Line , Chromatography, Paper , Culture Techniques , DNA Nucleotidyltransferases/antagonists & inhibitors , DNA, Neoplasm/biosynthesis , Leukemia L1210/enzymology , Mice , Neoplasm Transplantation , Nucleosides/analysis , Nucleotides/metabolism , Oxidoreductases/antagonists & inhibitors , Phosphotransferases/antagonists & inhibitors , RNA, Neoplasm/biosynthesis , Thymidine/analysis , Transplantation, Homologous , Tritium , Uridine/analysisABSTRACT
Mammalian cell culture systems were maintained free of mycoplasmas by using a 3-day agar plate test as a weekly routine to monitor the conditions of the cells. If contaminated cell cultures were found, they were discarded and replaced from a pleuropneumonia-like organism (PPLO)-free cell bank. PPLO-free lines were established by treatment with various antibiotics. The KB cell line was freed of mycoplasmas by treatment for 1 week with a mixture of chlortetracycline, kanamycin, and chloramphenicol. L-929 cells were cleared of contamination with either spectinomycin or tylosin, and a synovial cell line was cleared with lincomycin or tylosin. Each cell line, after eradication of the contaminant, was stored in liquid nitrogen. A number of agents were tested to determine minimal inhibitory concentration against three known and three unidentified mycoplasmas. Chlortetracycline and tetracycline were found to be highly active against all strains, whereas tylosin, spectinomycin, and lincomycin, though less active, were equally useful because of their low toxicity against cells. Kanamycin was highly active against three strains, but inactive at high levels against the KB cell contaminants. A disc plate test was used to check isolated cell contaminants for sensitivity to various agents.